Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate

Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate

FromKeeping Current CME


Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate

FromKeeping Current CME

ratings:
Length:
32 minutes
Released:
Nov 17, 2023
Format:
Podcast episode

Description

What strategies are you using to individualize treatment of HR+/HER2- early breast cancer? Credit available for this activity expires: 11/17/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998210?ecd=bdc_podcast_libsyn_mscpedu
Released:
Nov 17, 2023
Format:
Podcast episode

Titles in the series (100)

Hear from experts as they discuss timely clinical topics as well as relevant and actionable strategies for practice improvement. This podcast is available for CME credit.